Skip to Main Content

Paper Details

Point-of-care cell therapy manufacturing; it's not for everyone.
J Transl Med
3
2022
cancer, hemoglobinopathies, inherited immune deficiencies, patients, people, viral infections
Author NameAffiliation
David F StroncekCenter for Cellular Engineering, NIH Clinical Center
David F StroncekCenter for Cellular Engineering, NIH Clinical Center
  • 1 - 2

Datasets

Release 1.2